Cargando…

Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation

This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled....

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Tianqing, Ma, Xiaolu, Hu, Haoyun, Gong, Zhiyun, Zheng, Hui, Xie, Suhong, Guo, Lin, Lu, Renquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029686/
https://www.ncbi.nlm.nih.gov/pubmed/35448194
http://dx.doi.org/10.3390/curroncol29040220
_version_ 1784691941200363520
author Yan, Tianqing
Ma, Xiaolu
Hu, Haoyun
Gong, Zhiyun
Zheng, Hui
Xie, Suhong
Guo, Lin
Lu, Renquan
author_facet Yan, Tianqing
Ma, Xiaolu
Hu, Haoyun
Gong, Zhiyun
Zheng, Hui
Xie, Suhong
Guo, Lin
Lu, Renquan
author_sort Yan, Tianqing
collection PubMed
description This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled. Serological indicators preoperatively were collected. A risk model score (RMS) was constructed based on the levels of serological indicators determined by receiver operating characteristic curves. We correlated this RMS with EOC patients’ overall survival (OS). Finally, 635 patients were identified. Pearson’s χ(2) results showed that RMS was significantly related to clinical parameters. Kaplan–Meier analysis demonstrated that an RMS less than 3 correlated with a longer OS (p < 0.0001). Specifically, significant differences were perceived in the survival curves of different subgroups. Multivariate Cox analysis revealed that age (p = 0.015), FIGO stage (p = 0.006), ascites (p = 0.015) and RMS (p = 0.005) were independent risk factors for OS. Moreover, RMS combined with age, FIGO and ascites could better evaluate for patients’ prognosis in DCA analyses. Our novel RMS-guided classification preoperatively identified the prognostic subgroups of patients with EOC and showed higher accuracy than the conventional method, meaning that it could be a useful and economical tool for tailored monitoring and/or therapy.
format Online
Article
Text
id pubmed-9029686
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90296862022-04-23 Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation Yan, Tianqing Ma, Xiaolu Hu, Haoyun Gong, Zhiyun Zheng, Hui Xie, Suhong Guo, Lin Lu, Renquan Curr Oncol Article This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled. Serological indicators preoperatively were collected. A risk model score (RMS) was constructed based on the levels of serological indicators determined by receiver operating characteristic curves. We correlated this RMS with EOC patients’ overall survival (OS). Finally, 635 patients were identified. Pearson’s χ(2) results showed that RMS was significantly related to clinical parameters. Kaplan–Meier analysis demonstrated that an RMS less than 3 correlated with a longer OS (p < 0.0001). Specifically, significant differences were perceived in the survival curves of different subgroups. Multivariate Cox analysis revealed that age (p = 0.015), FIGO stage (p = 0.006), ascites (p = 0.015) and RMS (p = 0.005) were independent risk factors for OS. Moreover, RMS combined with age, FIGO and ascites could better evaluate for patients’ prognosis in DCA analyses. Our novel RMS-guided classification preoperatively identified the prognostic subgroups of patients with EOC and showed higher accuracy than the conventional method, meaning that it could be a useful and economical tool for tailored monitoring and/or therapy. MDPI 2022-04-12 /pmc/articles/PMC9029686/ /pubmed/35448194 http://dx.doi.org/10.3390/curroncol29040220 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yan, Tianqing
Ma, Xiaolu
Hu, Haoyun
Gong, Zhiyun
Zheng, Hui
Xie, Suhong
Guo, Lin
Lu, Renquan
Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title_full Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title_fullStr Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title_full_unstemmed Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title_short Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
title_sort serology-based model for personalized epithelial ovarian cancer risk evaluation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029686/
https://www.ncbi.nlm.nih.gov/pubmed/35448194
http://dx.doi.org/10.3390/curroncol29040220
work_keys_str_mv AT yantianqing serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT maxiaolu serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT huhaoyun serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT gongzhiyun serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT zhenghui serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT xiesuhong serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT guolin serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation
AT lurenquan serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation